ストックスクリーナーアプリを入手
14.00
2.04%
0.28
アフターアワーズ：
14.15
0.15
+1.07%
前日終値:
$13.72
開ける：
$13.8072
24時間の取引高:
10,082
Relative Volume:
0.26
時価総額：
$687.70M
収益：
-
当期純損益:
$-143.59M
株価収益率:
-4.9582
EPS:
-2.8236
ネットキャッシュフロー:
$-119.47M
1週間 パフォーマンス:
+17.65%
1か月 パフォーマンス:
-15.15%
6か月 パフォーマンス:
-34.12%
1年 パフォーマンス:
-33.96%
1日の値動き範囲:
$13.60
$14.30
1週間の範囲:
$11.66
$14.55
52週間の値動き範囲:
$11.51
$25.50
Pharvaris Nv Stock (PHVS) Company Profile
PHVS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PHVS
Pharvaris Nv
|
14.00 | 687.70M | 0 | -143.59M | -119.47M | -2.8236 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Pharvaris Nv Stock (PHVS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-09-25 | 開始されました | Wedbush | Outperform |
| 2023-08-15 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-05 | 開始されました | Bryan Garnier | Buy |
| 2022-09-13 | 再開されました | JMP Securities | Mkt Outperform |
| 2022-08-23 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-22 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-05-25 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-03-02 | 開始されました | BofA Securities | Neutral |
| 2021-03-02 | 開始されました | Morgan Stanley | Overweight |
| 2021-03-02 | 開始されました | Oppenheimer | Outperform |
| 2021-03-02 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Pharvaris Nv (PHVS) 最新ニュース
Where are the Opportunities in (PHVS) - news.stocktradersdaily.com
Pharvaris (NASDAQ:PHVS) Trading Down 8.4%Here's Why - MarketBeat
5,800 Shares in Pharvaris (NASDAQ:PHVS) Acquired by KLP Kapitalforvaltning AS - Defense World
Wedbush Issues Pessimistic Forecast for Pharvaris Earnings - Defense World
What is Leerink Partnrs’ Estimate for Pharvaris Q1 Earnings? - Defense World
What is Wedbush’s Forecast for Pharvaris FY2029 Earnings? - Defense World
Pharvaris NV reports results for the quarter ended December 31Earnings Summary - TradingView
Pharvaris Reports 2024 Financial Results and Business Progress - TipRanks
Pharvaris Accelerates HAE Drug Development: Phase 3 Trial Fully Enrolled, €281M War Chest - Stock Titan
Pharvaris (PHVS) Projected to Post Earnings on Wednesday - Defense World
(PHVS) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Pharvaris Says EU Orphan Designation Received for Deucrictibant - MarketScreener
Major EU Breakthrough: Pharvaris' Angioedema Drug Gains Coveted Orphan Status - Stock Titan
(PHVS) Technical Data - news.stocktradersdaily.com
Can Pharvaris Impress Investors at Upcoming Leerink Conference? - StockTitan
How to Take Advantage of moves in (PHVS) - Stock Traders Daily
We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth - Yahoo Finance
(PHVS) Trading Report - Stock Traders Daily
Pharvaris (NASDAQ:PHVS) Sees Significant Increase in Short Interest - MarketBeat
Pharvaris (NASDAQ:PHVS) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Pharvaris (NASDAQ:PHVS) Shares Gap DownWhat's Next? - MarketBeat
(PHVS) Investment Analysis - Stock Traders Daily
Pharvaris (NASDAQ:PHVS) Price Target Raised to $55.00 - MarketBeat
Barclays PLC Purchases New Holdings in Pharvaris (NASDAQ:PHVS) - Defense World
Why Is Andreas Halvorsen Bullish On Pharvaris N.V. (PHVS) Now? - Insider Monkey
FY2026 EPS Estimates for Pharvaris Decreased by Analyst - Defense World
Leerink Partnrs Brokers Cut Earnings Estimates for Pharvaris - MarketBeat
Billionaire Andreas Halvorsen’s Top 15 Long-Term Stock Picks - Insider Monkey
Pharvaris (NASDAQ:PHVS) Trading Up 5.3%What's Next? - MarketBeat
How To Trade (PHVS) - Stock Traders Daily
Pharvaris (NASDAQ:PHVS) Stock Price Down 11.7%Here's Why - MarketBeat
Pharvaris Advances Phase 3 HAE Programs, Expands Pipeline Into Acquired Angioedema Treatment - StockTitan
Geode Capital Management LLC Boosts Holdings in Pharvaris (NASDAQ:PHVS) - Defense World
Barclays PLC Takes Position in Pharvaris (NASDAQ:PHVS) - Defense World
(PHVS) Long Term Investment Analysis - Stock Traders Daily
Jane Street Group LLC Makes New Investment in Pharvaris (NASDAQ:PHVS) - Defense World
Jane Street Group LLC Acquires Shares of 28,418 Pharvaris (NASDAQ:PHVS) - MarketBeat
Pharvaris (NASDAQ:PHVS) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
State Street Corp Purchases New Shares in Pharvaris (NASDAQ:PHVS) - Defense World
53,980 Shares in Pharvaris (NASDAQ:PHVS) Bought by State Street Corp - MarketBeat
Pharvaris (NASDAQ:PHVS) Trading Down 3.5%Here's Why - MarketBeat
Pharvaris: Despite 30% Decline, Still Fair At Best (NASDAQ:PHVS) - Seeking Alpha
Pharvaris (NASDAQ:PHVS) Sees Large Decrease in Short Interest - MarketBeat
Trend Tracker for (PHVS) - Stock Traders Daily
Pharvaris (PHVS) Shares Cross Above 200 DMA - Nasdaq
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Invests $906,000 in Pharvaris (NASDAQ:PHVS) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Makes New $906,000 Investment in Pharvaris (NASDAQ:PHVS) - MarketBeat
Learn to Evaluate (PHVS) using the Charts - Stock Traders Daily
Pharvaris (PHVS) Price Target Increased by 38.65% to 32.93 - MSN
Pharvaris Nv (PHVS) 財務データ
収益
当期純利益
現金流量
EPS
2.51%
大文字化:
|
ボリューム (24 時間):